Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (6): 480-485.doi: 10.35541/cjd.20210813
• Original Articles • Previous Articles Next Articles
Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue
Received:
2021-11-09
Revised:
2022-04-05
Online:
2022-06-15
Published:
2022-06-02
Contact:
Wang Mingyue
E-mail:wangmy@pku.edu.cn
Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study[J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485.doi:10.35541/cjd.20210813
[1] | Schmidt E, Zillikens D. Pemphigoid diseases[J]. Lancet, 2013,381(9863):320⁃332. doi: 10.1016/S0140⁃6736(12)61140⁃4. |
[2] | Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the pemphigoid diseases[J]. J Eur Acad Dermatol Venereol, 2019,33(9):1685⁃1694. doi: 10.1111/jdv.15679. |
[3] | Bağcı IS, Horváth ON, Ruzicka T, et al. Bullous pemphigoid[J]. Autoimmun Rev, 2017,16(5):445⁃455. doi: 10.1016/j.autrev. 2017.03.010. |
[4] | Milani⁃Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review[J]. Eur J Dermatol, 2017,27(5):472⁃481. doi: 10.1684/ejd.2017.3066. |
[5] | Teraki Y, Hotta T, Shiohara T. Skin⁃homing interleukin⁃4 and ⁃13⁃producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin⁃10⁃producing cells[J]. J Invest Dermatol, 2001,117(5):1097⁃1102. doi: 10.1046/j.0022⁃202x.2001.01505.x. |
[6] | Geller S. Interleukin 4 and interleukin 13 inhibition: a promising therapeutic approach in bullous pemphigoid[J]. J Am Acad Dermatol, 2020,83(1):37⁃38. doi: 10.1016/j.jaad.2020.03. 017. |
[7] | Hamilton JD, Suárez⁃Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate⁃to⁃severe atopic dermatitis[J]. J Allergy Clin Immunol, 2014,134(6):1293⁃1300. doi: 10.1016/j.jaci.2014.10.013. |
[8] | Russo R, Cozzani E, Gasparini G, et al. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases?[J]. Dermatol Ther, 2020,33(1):e13190. doi: 10.1111/dth.13190. |
[9] | Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016,375(24):2335⁃2348. doi: 10.1056/NEJMoa1610020. |
[10] | Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal⁃epidermal junction targeted by autoantibodies in pemphigoid diseases[J]. Exp Dermatol, 2017,26(12):1154⁃1162. doi: 10.1111/exd.13446. |
[11] | Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid[J]. Annu Rev Pathol, 2016,11:175⁃197. doi: 10.1146/annurev⁃pathol⁃012615⁃044313. |
[12] | Iwata H, Kamio N, Aoyama Y, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180⁃kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment[J]. J Invest Dermatol, 2009,129(4):919⁃926. doi: 10.1038/jid.2008.305. |
[13] | Saniklidou AH, Tighe PJ, Fairclough LC, et al. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review[J]. Arch Dermatol Res, 2018,310(1):11⁃28. doi: 10.1007/s00403⁃017⁃1789⁃1. |
[14] | Kalowska M, Ciepiela O, Kowalewski C, et al. Enzyme⁃linked immunoassay index for anti⁃NC16a IgG and IgE auto⁃antibodies correlates with severity and activity of bullous pemphigoid[J]. Acta Derm Venereol, 2016,96(2):191⁃196. doi: 10.2340/00015 555⁃2101. |
[15] | Cozzani E, Gasparini G, Di Zenzo G, et al. Immunoglobulin E and bullous pemphigoid[J]. Eur J Dermatol, 2018,28(4):440⁃448. doi: 10.1684/ejd.2018.3366. |
[16] | Messingham KN, Srikantha R, DeGueme AM, et al. FcR⁃independent effects of IgE and IgG autoantibodies in bullous pemphigoid[J]. J Immunol, 2011,187(1):553⁃560. doi: 10.4049/jimmunol.1001753. |
[17] | Giomi B, Caproni M, Calzolari A, et al. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid[J]. J Dermatol Sci, 2002,30(2):116⁃128. doi: 10.1016/s0923⁃1811(02)00067⁃1. |
[18] | Simon D, Borradori L, Simon HU. Eosinophils as putative therapeutic targets in bullous pemphigoid[J]. Exp Dermatol, 2017,26(12):1187⁃1192. doi: 10.1111/exd.13416. |
[19] | Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia[J]. J Am Acad Dermatol, 1983,8(5):648⁃651. doi: 10.1016/s0190⁃9622(83)70073⁃3. |
[20] | Wakugawa M, Nakamura K, Hino H, et al. Elevated levels of eotaxin and interleukin⁃5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia[J]. Br J Dermatol, 2000,143(1):112⁃116. doi: 10.1046/j.1365⁃2133.2000.03599.x. |
[21] | Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid[J]. J Am Acad Dermatol, 2020,83(1):53⁃62. doi: 10.1016/j.jaad.2019.07.060. |
[22] | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识(2022)[J]. 中华皮肤科杂志, 2022,55(1):1⁃11. doi: 10.35541/cjd.20210532. |
[23] | Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid[J]. JAMA Dermatol, 2018,154(10):1225⁃1226. doi: 10.1001/jamadermatol.2018.2526. |
[24] | Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series[J]. J Am Acad Dermatol, 2020,83(1):46⁃52. doi: 10.1016/j.jaad.2020.01.089. |
[25] | Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus[J]. Dermatol Online J, 2019,25(11) :13030/qt25q9w6r9. |
[26] | Seyed Jafari SM, Feldmeyer L, Bossart S, et al. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid[J]. Front Immunol, 2020,11:611549. doi: 10.3389/fimmu.2020.611549. |
[27] | Saleh M, Reedy M, Torok H, et al. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature[J]. Dermatol Online J, 2021,27(4):13030/qt0dv3f9h6. |
[28] | Velin M, Dugourd PM, Sanchez A, et al. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study[J]. J Eur Acad Dermatol Venereol, 2022. doi: 10.1111/jdv.17999. |
[29] | Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab⁃induced bullous pemphigoid: a case report and review of the literature[J]. Dermatol Online J, 2021,27(9). doi: 10.5070/D327955136. |
[30] | Zhang Y, Xu Q, Chen L, et al. Efficacy and safety of dupilumab in moderate⁃to⁃severe bullous pemphigoid[J]. Front Immunol, 2021,12:738907. doi: 10.3389/fimmu.2021.738907. |
[31] | 杨璐, 曾跃平, 晋红中. 度普利尤单抗联合糖皮质激素治疗大疱性类天疱疮:国内首报并文献复习[J]. 中华临床免疫和变态反应杂志, 2021,15(1):47⁃52. doi: 10.3969/j.issn.1673⁃8705. 2021.01.009. |
[32] | 潘春梅, 潘萌, 冯雨苗, 等. 度普利尤单抗治疗难治性大疱性类天疱疮1例[J]. 中国皮肤性病学杂志, 2022,36(3):311⁃314. |
[1] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(6): 508-510. |
[2] | Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470. |
[3] | Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493. |
[4] | Zhang Xiao, Chen Fengming, Liu Lin, Luo Li, Guo Jin, Gao Tianwen, Shi Qiong. Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394. |
[5] | Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462. |
[6] | Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372. |
[7] | Li Wei, Yin Huibin. Heterogeneity across skin sites in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 349-352. |
[8] | Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303. |
[9] | Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298. |
[10] | Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology. Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 289-294. |
[11] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
[12] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
[13] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022) [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
[14] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
[15] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
|